1. Home
  2. SACH vs ATNM Comparison

SACH vs ATNM Comparison

Compare SACH & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sachem Capital Corp.

SACH

Sachem Capital Corp.

N/A

Current Price

$1.08

Market Cap

48.6M

Sector

Real Estate

ML Signal

N/A

Logo Actinium Pharmaceuticals Inc. (Delaware)

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

N/A

Current Price

$1.19

Market Cap

36.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SACH
ATNM
Founded
2010
2000
Country
United States
United States
Employees
29
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
48.6M
36.8M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
SACH
ATNM
Price
$1.08
$1.19
Analyst Decision
Hold
Strong Buy
Analyst Count
3
1
Target Price
$2.00
$4.00
AVG Volume (30 Days)
128.9K
115.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
18.52%
N/A
EPS Growth
N/A
30.60
EPS
N/A
N/A
Revenue
N/A
$81,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$1.17
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.80
$1.02
52 Week High
$1.35
$1.95

Technical Indicators

Market Signals
Indicator
SACH
ATNM
Relative Strength Index (RSI) 69.14 52.28
Support Level $1.04 $1.02
Resistance Level $1.13 $1.71
Average True Range (ATR) 0.03 0.07
MACD 0.01 0.02
Stochastic Oscillator 72.03 77.78

Price Performance

Historical Comparison
SACH
ATNM

About SACH Sachem Capital Corp.

Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Share on Social Networks: